MedTrace Logo

Safety and Pharmacokinetics of SNX-001 in Healthy Aged Volunteers

NCT01269476 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 27

Last updated 2011-01-04

No results posted yet for this study

Summary

This is a randomised, double-blind, group-sequential, placebo-controlled, safety and pharmacokinetic study in healthy, aged volunteers.

Objectives:

1. to confirm the previously reported safety profile of oral SNX-001 after single and multiple doses of 3.6, 7.2 or 10.8 mg compared to placebo
2. to establish SNX-001 pharmacokinetic profile.

Conditions

  • Safety

Interventions

DRUG

SNX-001

3.6, 7.2, or 10.8 mg single dose or t.i.w.

DRUG

Placebo

Same volumes and frequency as active.

Sponsors & Collaborators

  • SeneXta Therapeutics SA

    lead INDUSTRY

Principal Investigators

  • Jorg Sahlmann, MD · Scope Life Sciences GmbH

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
50 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2009-12-31
Primary Completion
2010-06-30
Completion
2010-08-31

Countries

  • Germany

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01269476 on ClinicalTrials.gov